

PSJ3

Exhibit 19

ABC Meeting-NACDS

Introductions

1) Suspicious Order Monitoring (SOM) practices at ABC

- can you briefly explain the metrics and process involved for your pharmacies?
- have there been any recent requirements or changes from the FDA?
- is there an exception process?
- who designs and enforces?
- do you give your retail customers visibility into the process or rules?
- what expectations do retail customers have regarding Cll access?
- how can we ensure legitimate patients and providers have access to appropriate therapy?
- are there any best practices you've seen from other manufactures which have helped the process?
- how does recent focus on Clls affect your business

2) Q2 DSA Payment-ABC & Bellco Combined

- net sales \$115.6 million (\$112.4 from ABC)
- service fee of 2.9995%
- total service fee of \$3.347 million
- inventory management only component not at 100% with two products out of Compliance (Percodan Tabs and Percocet 7.5/500mg)

3) Top to Top meeting update

- have there been any additional communications?
- what do you feel the next step should be in the partnership?
- communications going forward will go through Akin and me

4) Questions?